Nicotine replacement therapy lozenge

Phase 2

Nicotine replacement therapy lozenge is one of 2 therapeutic programs targeting Dual Use of Cigarettes and E-cigarettes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Dual Use of Cigarettes and E-CigarettesNot yet recruiting

Dual Use of Cigarettes and E-CigarettesPhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Dual Use of Cigarettes and E-Cigarettes

#DrugCompanyPhaseTrials

Nicotine Replacement Therapy

VVA Office of Research and Development

Phase 2

1 2

Nicotine replacement therapy lozenge

MMedical University of South Carolina

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Not yet recruiting

Dual Use of Cigarettes and E-Cigarettes

NCT07754578

Clinical

Trials by Indication[1]

Dual Use of Cigarettes and E-cigarettes1 trial

High-Dose Nicotine Replacement Therapy for Quitting Cigarettes and E-cigarettes

Not yet recruiting·MMedical University of South Carolina·Phase 2·NCT07754578·321 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nicotine replacement therapy lozenge. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nicotine replacement therapy lozenge. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Medical University of South Carolina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMedical University of South Carolina

Nicotine replacement therapy lozenge

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Dual Use of Cigarettes and E-cigarettes1 trial

References

Drug Info

Quick Facts

Related News